Skip to content
value.today

Normoxys Inc.

🇺🇸 Brighton, Massachusetts, USAPharmaceuticalsFounded 2004

Formerly Oxyplus Inc

Total raised
$22 M
2 rounds on record
Latest round
$18 M
May 2010
First round on record
Apr 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Normoxys Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2010$18 MNo. 2$10 to $50 million

Normoxys Inc.: Raise no. 2, May 2010

Investors in this round

15 investors had bought by the notice of May 25, 2010: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Conrad Bletzer, Jr. · Executive Officer
  • Martin Tolar · Executive Officer, Director
  • Claude Nicolau · Director
  • Francesco De Rubertis · Director
  • Jean-Marie Lehn · Director
  • Jean-Pierre Garnier · Director
  • Michele Ollier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin Tolar, President and chief executive officer. Source: SEC Form D, newest notice filed May 25, 2010. Read the notice at the SEC.

equitySEC
Apr 2009$5 MNo. 1$2 to $10 million

Normoxys Inc.: Raise no. 1, Apr 2009

Investors in this round

5 investors had bought by the notice of Apr 29, 2009: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Conrad J. Bletzer, Jr. · Executive Officer, Director
  • Claude Nicolau · Director
  • Dr. Jean-Pierre Garnier · Director
  • Francesco De Rubertis · Director
  • Jean-Marie Lehn · Director
  • Michele Ollier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Conrad J. Bletzer, Jr., President and chief executive officer. Source: SEC Form D, newest notice filed Apr 29, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Normoxys Inc. chose not to state its revenue in its newest notice of a funding round (May 2010).

    SEC Form D · May 2010

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2010

That is all the official record says: Normoxys Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Normoxys Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Normoxys Inc.
NameRoleNamed in
Conrad Bletzer, Jr.Executive officerMay 2010
Martin TolarExecutive officerMay 2010
Conrad J. Bletzer, Jr.Executive officerApr 2009
Claude NicolauDirectorMay 2010
Francesco De RubertisDirectorMay 2010
Jean-Marie LehnDirectorMay 2010
Jean-Pierre GarnierDirectorMay 2010
Martin TolarDirectorMay 2010
Michele OllierDirectorMay 2010
Conrad J. Bletzer, Jr.DirectorApr 2009
Dr. Jean-Pierre GarnierDirectorApr 2009